Skip to main content

SCD Patients Treatment

SCD patients free of VOEs after treatment with gene-editing therapy


Nearly all the patients with severe sickle cell disease (SCD) who were treated with renizgamglogene autogedtemcel (reni-cel) remained free of vaso-occlusive events (VOEs) for up to two years, new data from the Phase 1/2/3 RUBY clinical trial shows.

The treatment also increased total hemoglobin levels and was well tolerated, according to a company press release from Editas Medicine, the developer of the gene-editing therapy.

Data from 28 patients was presented at the Annual Meeting and Exposition of the American Society of Hematology (ASH) in a poster presentation titled, “Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial.” The presentation was made by Rabi Hanna, MD, from the department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation at Cleveland Clinic Children’s hospital.

SCD is caused by mutations in the HBB gene that lead to the production of a defective version of adult hemoglobin, the protein that transports oxygen in red blood cells. As a result, the cells take on a sickle-like shape and die prematurely (hemolysis), often causing patients to develop anemia, one of the most common SCD symptoms.

People with SCD may also experience VOEs, which include painful vaso-occlusive crises (VOCs) and other complications that occur when sickled cells obstruct blood vessels and block blood flow, depriving tissues of oxygen.

Reni-cel, formerly EDIT-301, was designed to increase the production of fetal hemoglobin (HbF), a type that’s typically made during early fetal development and is more efficient at carrying oxygen than the protein’s adult version.

What is reni-cel gene-editing therapy?

The treatment involves collecting hematopoietic stem cells — which are capable of giving rise to all types of blood cells — from a patient’s bone marrow and modifying them to introduce genetic changes that mimic those naturally found in people with hereditary persistence of fetal hemoglobin, a benign condition where HbF production persists into adulthood.

After a course of chemotherapy to destroy stem cells in the bone marrow and make room for the modified ones, the engineered stem cells are infused back into the patient via a stem cell transplant. These modified stem cells are then expected to give rise to red blood cells that can produce HbF, which should reduce red blood cell sickling and the frequency of VOEs.

The Phase 1/2/3 RUBY trial (NCT04853576) is evaluating the safety and efficacy of a single infusion of reni-cel in patients with severe SCD, which is defined as those having at least two severe VOEs that require medical attention per year in the two years before entering the study. The patients, who researchers described as “broadly representative of the overall population of patients with severe SCD,” were a mean age of 26.1 and more than half were women (53.6%). In the two years before enrolling they had a mean of 4.6 severe VOEs a year.

Consistent with previous data, all but one patient remained free of VOEs from the time they received treatment, with the follow-up ranging from about 21 days to 25.5 months, or about two years. Moreover, after six months, the patients’ total hemoglobin levels increased to a mean of 13.8 g/dL, and HbF levels reached 48.1%. The mean percentage of HbF-producing red blood cells increased early and was maintained above 90% from four months post-treatment up to the last follow-up.

Also, mean corpuscular fetal hemoglobin, the average fetal hemoglobin levels, in HbF-producing red blood cells increased early and remained above the sickling threshold of 10 picograms per cell through the last follow-up. Markers of hemolysis reduced or normalized six months after treatment and generally remained the same at the last evaluation.

Sustained clinically meaningful improvements in patient-reported outcomes were also reported after treatment across several domains, including pain, physical function, social roles and activities.

Transplanted stem cells survived and expanded within the bone marrow in all the evaluated patients. The treatment was also well tolerated, with the therapy’s safety profile being consistent with a stem cell transplant and chemotherapy conditioning with busulfan.

Two serious adverse events were considered to be possibly related to reni-cel: a case of cute respiratory distress syndrome and another of eosinophilic gastroenteritis, a gastrointestinal disease.

Sickle Cell Disease, hemoglobinopathy, sickle hemoglobin, red blood cell deformity, vaso-occlusion, chronic hemolysis, anemia, oxidative stress, genetic mutation, hemoglobin S, pain crisis, hydroxyurea therapy, bone marrow transplant, disease management, erythrocyte dysfunction, ischemia-reperfusion injury, pediatric hematology, genetic counseling, stroke in SCD, organ damage, fetal hemoglobin, quality of life, inflammation in SCD, sickle cell trait, patient advocacy, public health,

#SickleCellDisease #SCD #Hemoglobinopathy #RedBloodCells #VasoOcclusion #Anemia #GeneticDisorder #HemoglobinS #PainCrisis #Hydroxyurea #BoneMarrowTransplant #DiseaseManagement #PediatricHematology #GeneticCounseling #StrokeSCD #ChronicHemolysis #FetalHemoglobin #OrganDamage #Inflammation #SickleCellTrait #OxidativeStress #PatientAdvocacy #PublicHealth #QualityOfLife #SickleCellAwareness

Comments

Post a Comment

Popular posts from this blog

Genetics role in ovarian cancer

The Medical Minute: Genetics play big role in ovarian cancer In 2024, about 19,680 women in the United States will receive a new diagnosis of ovarian cancer and 12,740 women will die from the disease, said Dr. Shaina Bruce , a gynecologic oncologist at Penn State Cancer Institute . The median age of all patients who develop ovarian cancer is 63. Historically, women at increased risk for ovarian cancer are recommended to have their fallopian tubes and ovaries removed when they have completed having children. Taking that step to protect themselves comes at a heavy price ― surgical menopause. But Bruce said medical science is catching up with ovarian cancer. Studies could lead to new methods for preventative care and the surgery needed to lower risk may be easier than it once was. Below, during Gynecologic Cancer Awareness Month, Bruce discusses the disease and why acting to reduce your risk is worth it. What’s the connection between heredity and ovarian cancer? About 25% of all cases of ...
Post a Comment
Read more

X chromosome

Gene on the X chromosome may help explain high multiple sclerosis rates in women Brain inflammation may be fueled by a gene on the X chromosome, a new study in mice suggests. And in female mice, who carry two X chromosomes, a diabetes drug called metformin may work to counteract that inflammation. If these findings bear out in later studies, they could help to unravel the long-standing mystery of why women, who have two copies of this inflammation-driving gene, are more prone to certain autoimmune diseases, particularly after menopause. A disparity between the sexes Our bodies are patrolled by immune cells that provide protection against bacteria and viruses, but sometimes, these defenses turn on us. In the autoimmune disorder multiple sclerosis (MS), for instance, the immune system attacks myelin, the fatty insulation surrounding the nerve fibers in the brain and spinal cord. This leads to symptoms such as muscle weakness and difficulty walking, as well issues with memory and thinking...
Post a Comment
Read more

Multifactorial Genetic Conditions

Multifactorial Genetic Conditions Multifactorial genetic conditions are disorders caused by the combined effects of multiple genes and environmental factors , rather than a single gene mutation . These conditions do not follow classic Mendelian inheritance patterns and instead result from complex gene–environment interactions . Factors such as lifestyle, nutrition, infections, stress, and exposure to toxins can significantly influence disease onset and severity in genetically susceptible individuals. Common examples include diabetes, cardiovascular diseases , neural tube defects, asthma, and many neuropsychiatric disorders. Understanding multifactorial inheritance is essential for risk prediction, preventive medicine, and personalized healthcare strategies. Multifactorial inheritance, polygenic traits, gene–environment interaction, complex diseases, genetic susceptibility, environmental risk factors, non-Mendelian inheritance, disease predisposition, polygenic risk score, precision ...
Post a Comment
Read more